Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas
Open accessThe DOI matches its Crossref record.
Abstract
Previous studies with temozolomide suggest that a prolonged duration of chemotherapy is important for treating low-grade gliomas (LGGs). PCV (procarbazine, CCNU, vincristine) chemotherapy has demonstrated efficacy in treating LGGs, but this therapy cannot be used for a prolonged period because of the cumulative toxicity. The aim of the present study was to evaluate the impact of first-line PCV chemotherapy on LGGs growth kinetics. The mean tumor diameter (MTD) of 21 LGGs was measured on serial magnetic resonance images before (n=13), during, and after PCV onset (n=21). During PCV treatment, a decrease in the MTD was observed in all patients. After PCV discontinuation, an ongoing decrease in MTD was observed in 20 of the 21 patients. Median duration of the MTD decrease was 3.4 years (range, 0.8-7.7) after PCV onset and 2.7 years (range, 0-7) after the end of PCV treatment with 60% of LGGs, demonstrating an ongoing and prolonged (>2 years) response despite chemotherapy no longer being administered. According to McDonald's criteria, the rates of partial and minor responses were 5% and 38% at the end of PCV but 38% and 42% at the time of maximal MTD decrease, which occurred after a median period of 3.4 years after PCV onset. These results challenge the idea that a prolonged duration of chemotherapy is necessary for treating LGGs and raise the issue of understanding the mechanisms involved in the persistent tumor volume decrease once chemotherapy is terminated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Self-citationHerrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.-D., Krex, D., Grauer, O., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 568
Capelle, L., Fontaine, D., Mandonnet, E., Taillandier, L., Golmard, J. L., Bauchet, L., Pallud, J., Peruzzi, P., Baron, M. H., Kujas, M., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.1.jns121 · Cited by 422
Self-citationVelocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos331 · Cited by 173
Self-citationPallud, J., Taillandier, L., Capelle, L., Fontaine, D., Peyre, M., Ducray, F., Duffau, H., & Mandonnet, E. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31826213de · Cited by 135
Self-citation
Metadata
- Authors
- Peyre, M., Cartalat-Carel, S., Meyronet, D., Ricard, D., Jouvet, A., Pallud, J., Mokhtari, K., Guyotat, J., Jouanneau, E., Sunyach, M.-P., Frappaz, D., Honnorat, J., & Ducray, F.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-20
- Volume
- 12
- Issue
- 10
- Pages
- 1078-1082
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2129849427
- Cited by
- 95
- References
- 0
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. https://app.cochat.ai/papers/10.1093/neuonc/noq055
- The paper
- Peyre, M., Cartalat-Carel, S., Meyronet, D., Ricard, D., Jouvet, A., Pallud, J., Mokhtari, K., Guyotat, J., Jouanneau, E., Sunyach, M.-P., Frappaz, D., Honnorat, J., & Ducray, F. (2010). Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noq055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.